Tradestie Institutional Equity Comparison Engine · Market Close May 07, 2026

EKSO vs EXPI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EXPI Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–1 Matrix Metrics)

EXPI Overall Winner 6-Pillar Tally: EKSO 0 – 6 EXPI Matrix Metrics: EKSO 1 – 7 EXPI

As of May 07, 2026, eXp World Holdings, Inc. (EXPI) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas EXPI carries 67.2/100 (BUY) at $6.74 (N/M Forward P/E, -1.1% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EKSO vs EXPI
EKSO NASDAQ
Ekso Bionics Holdings, Inc. Common Stock
General Industrial Machinery & Equipment, Nec
$11.80
+0.08% 1D
Market Cap $42.0M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 2.16β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 60
RSI-14: 60.4 · SMA20: $10.56 · SMA50: $10.65
EXPI NASDAQ Head-to-Head Winner
eXp World Holdings, Inc. Common Stock
Real Estate Agents & Managers (For Others)
$6.74
+3.37% 1D
Market Cap $1.0B
TTM Revenue $4.77B
Forward P/E N/M
Beta / 30D Vol 1.23β · 39% Vol
Unified Composite Score
67.2 / 100 BUY
Tech 75.0 Fund 67.0 Flow 67.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 59
RSI-14: 59.4 · SMA20: $6.38 · SMA50: $6.28

6-Pillar Scorecard Institutional Category Breakdown (EKSO 0 – 6 EXPI)

Columns: Metric · EKSO · EXPI
1. Valuation Multiples EXPI
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.3x 0.2x
2. Growth & Scale EXPI
Revenue Growth (YoY) -38.3% +8.5%
Earnings Growth (YoY) +0.0% +39.8%
TTM Revenue (USD) $13M $4.77B
Market Cap $42.0M $1.0B
3. Profitability & Quality EXPI
Gross Margin 53.5% 7.0%
Operating Margin -119.7% -1.1%
Net Profit Margin -91.4% -0.5%
Return on Equity (ROE) -107.6% -10.2%
4. Balance Sheet & Cash Flow EXPI
Cash Generation (TTM) -$11M EBITDA $90M
Cash Flow Margin -86.0% EBITDA Mgn 1.9%
Net Cash / Leverage $2.54 Book/Sh · -107.6% ROE $1.51 Book/Sh · -10.2% ROE
Dividend Yield None (0.00%) 3.18%
5. Options & Positioning EXPI
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 61.9% (<1st %ile)
Put/Call OI Skew N/A 0.10x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat EXPI
OpEx & R&D Intensity N/A 8.1% of Rev ($387M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Real Estate Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EKSO (1) vs EXPI (7)
Institutional Metric EKSO EXPI Criterion Row Edge
Market Capitalization
Scale
$42.0M $1.0B Larger Scale EXPI
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-38.3% +8.5% Higher Growth EXPI
Operating Margin (TTM)
Profitability
-119.7% -1.1% Higher Margin EXPI
Net Profit Margin
Profitability
-91.4% -0.5% Higher Margin EXPI
Return on Equity (ROE)
Capital Efficiency
-107.6% -10.2% Higher ROE EXPI
52-Week Range Position
Momentum
87% ($0–$14) 16% ($6–$12) Stronger Trend EKSO
Beta / 30D Volatility
Risk Regime
2.16β · 76% Vol 1.23β · 39% Vol Lower Realized Risk EXPI
Unified Institutional Score
Composite Signal
58.1 / 100 (HOLD) 67.2 / 100 (BUY) Higher Composite EXPI
Trailing 12M Revenue (USD)
Operating Scale
$13M $4.77B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
53.5% 7.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.3x EV/Rev N/M PEG · 0.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($2.54 Book/Sh · -107.6% ROE) $90M ($1.51 Book/Sh · -10.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EKSO +19.78 pp
EKSO: +25.53% · EXPI: +5.75%
3M Horizon EKSO +55.78 pp
EKSO: +25.93% · EXPI: -29.85%
6M Horizon EKSO +169.24 pp
EKSO: +131.37% · EXPI: -37.87%
1Y Horizon EKSO +109.59 pp
EKSO: +81.68% · EXPI: -27.91%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EKSO vs EXPI. Trailing 12-month operating profitability (EKSO -119.7% vs EXPI -1.1%) and valuation multiples (EKSO N/M vs EXPI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EKSO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross Margin53.5%
Op. Margin-119.7%
ROE / Fwd P/E-107.6% · N/M
EXPI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.77B
Gross Margin7.0%
Op. Margin-1.1%
ROE / Fwd P/E-10.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EKSO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EKSO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EXPI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 61.9%
IV Percentile <1st %ile
Put/Call OI Skew 0.10x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EXPI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EKSO Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $42.0M market capitalization and -119.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EXPI Moat Profile Cyclical / Execution-Driven Positioning
Real Estate Services Operator
Competes within the Real Estate Services value chain with $1.0B market capitalization and -1.1% operating margin.
OpEx & R&D Reinvestment 8.1% of Rev ($387M)
90D Engineering Disclosures 0 Published

Investor FAQ EKSO vs EXPI Key Questions & Quantitative Answers

As of May 07, 2026, eXp World Holdings, Inc. (EXPI) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas EXPI carries 67.2/100 (BUY) at $6.74 (N/M Forward P/E, -1.1% operating margin). Technically, EKSO sits in a Markup phase (RSI 60.4, UNCLASSIFIED options structure) and EXPI sits in a Neutral phase (RSI 59.4, UNCLASSIFIED options structure).

EXPI leads the Growth & Scale pillar: EKSO posts -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin), compared with EXPI at +8.5% YoY revenue growth and +39.8% YoY earnings growth on $4.77B TTM revenue (7.0% gross margin, -1.1% operating margin). On trailing 12-month operating scale, EKSO generates $13M in USD-normalized revenue versus $4.77B for EXPI. In operating R&D and SG&A reinvestment, EKSO deploys N/A (0 90-day corporate R&D disclosures) versus 8.1% of Rev ($387M) (0 disclosures) for EXPI.

EXPI screens cheaper on headline valuation multiples. EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin), whereas EXPI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.2x EV/Revenue (1.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EKSO (-107.6% ROE) versus EXPI (-10.2% ROE) capital efficiency.

In options market volatility and institutional positioning, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk). By comparison, EXPI carries 61.9% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.10x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.23β · 39% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of May 07, 2026. For educational research only; not investment advice.